Advances in graft-versus-host disease prevention strategies: latest updates from the 2022 ASH annual meeting

This review summarizes the significant advancements in prophylaxis against graft-versus-host disease (GvHD) presented at the 2022 ASH Annual Meeting. The use of innovative agents and regimens, along with the conventional prophylactic approach of combining post-transplant cyclophosphamide and anti-th...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Yiyin, Xu, Yang, Wu, Depei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10326945/
https://www.ncbi.nlm.nih.gov/pubmed/37420283
http://dx.doi.org/10.1186/s40164-023-00425-y
_version_ 1785069530587856896
author Chen, Yiyin
Xu, Yang
Wu, Depei
author_facet Chen, Yiyin
Xu, Yang
Wu, Depei
author_sort Chen, Yiyin
collection PubMed
description This review summarizes the significant advancements in prophylaxis against graft-versus-host disease (GvHD) presented at the 2022 ASH Annual Meeting. The use of innovative agents and regimens, along with the conventional prophylactic approach of combining post-transplant cyclophosphamide and anti-thymocyte globulin, were discussed. The innovative agents and regimens highlighted in this review include abatacept, the first FDA-approved drug for acute GvHD prophylaxis; RGI-2001, which promotes the expansion of regulatory T cells; and cell therapies such as Orca-T and Orca-Q. These advancements provide promising strategies and options for GvHD prevention, offering hope for improved post-transplant patient outcomes in terms of survival rates.
format Online
Article
Text
id pubmed-10326945
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-103269452023-07-08 Advances in graft-versus-host disease prevention strategies: latest updates from the 2022 ASH annual meeting Chen, Yiyin Xu, Yang Wu, Depei Exp Hematol Oncol Correspondence This review summarizes the significant advancements in prophylaxis against graft-versus-host disease (GvHD) presented at the 2022 ASH Annual Meeting. The use of innovative agents and regimens, along with the conventional prophylactic approach of combining post-transplant cyclophosphamide and anti-thymocyte globulin, were discussed. The innovative agents and regimens highlighted in this review include abatacept, the first FDA-approved drug for acute GvHD prophylaxis; RGI-2001, which promotes the expansion of regulatory T cells; and cell therapies such as Orca-T and Orca-Q. These advancements provide promising strategies and options for GvHD prevention, offering hope for improved post-transplant patient outcomes in terms of survival rates. BioMed Central 2023-07-07 /pmc/articles/PMC10326945/ /pubmed/37420283 http://dx.doi.org/10.1186/s40164-023-00425-y Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Correspondence
Chen, Yiyin
Xu, Yang
Wu, Depei
Advances in graft-versus-host disease prevention strategies: latest updates from the 2022 ASH annual meeting
title Advances in graft-versus-host disease prevention strategies: latest updates from the 2022 ASH annual meeting
title_full Advances in graft-versus-host disease prevention strategies: latest updates from the 2022 ASH annual meeting
title_fullStr Advances in graft-versus-host disease prevention strategies: latest updates from the 2022 ASH annual meeting
title_full_unstemmed Advances in graft-versus-host disease prevention strategies: latest updates from the 2022 ASH annual meeting
title_short Advances in graft-versus-host disease prevention strategies: latest updates from the 2022 ASH annual meeting
title_sort advances in graft-versus-host disease prevention strategies: latest updates from the 2022 ash annual meeting
topic Correspondence
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10326945/
https://www.ncbi.nlm.nih.gov/pubmed/37420283
http://dx.doi.org/10.1186/s40164-023-00425-y
work_keys_str_mv AT chenyiyin advancesingraftversushostdiseasepreventionstrategieslatestupdatesfromthe2022ashannualmeeting
AT xuyang advancesingraftversushostdiseasepreventionstrategieslatestupdatesfromthe2022ashannualmeeting
AT wudepei advancesingraftversushostdiseasepreventionstrategieslatestupdatesfromthe2022ashannualmeeting

Ejemplares similares